AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23590407
Drug: Experimental pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental pain model (hypertonic saline injection in infrapatellar fat pad)
Trial: 23590407
Drug: Control (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isotonic saline injection in contralateral infrapatellar fat pad)
Trial: 17357053
Drug: 3-drug EFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-drug EFV regimen (zidovudine/lamivudine plus EFV)
Trial: 17357053
Drug: 4-drug EFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug EFV regimen (zidovudine/lamivudine/abacavir plus EFV)
Trial: 16859064
Drug: Pyridoxine (5-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (5-100 mg/day)
Trial: 10759911
Drug: Zolmitriptan, 5
RxNorm normalized name: Zolmitriptan, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan, 5 mg
Trial: 10849042
Drug: Rizatriptan, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan, 10 mg
Trial: 8656666
Drug: cilazapril, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril, 5 mg once daily
Trial: 8656666
Drug: atenolol, 100
RxNorm normalized name: Atenolol, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol, 100 mg once daily
Trial: 6285721
Drug: Topical 5
RxNorm normalized name: urea topical 50% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5 percent acyclovir in polyethylene glycol
Trial: 19323930
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin (80 mg simvastatin for 7 days)
Trial: 11158043
Drug: Aldosterone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone (0.5 mg) after esmolol pretreatment
Trial: 11158043
Drug: Aldosterone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone (0.5 mg) after dobutamine pretreatment
Trial: 9576193
Drug: Intensive induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive induction and consolidation chemotherapy (4 courses)
Trial: 7889896
Drug: Short-stay (SS)
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-stay (SS) group, discharged immediately (mean 18 days) for standard Health Service care at home for 6 months plus high-energy supplement (3.31 MJ with 20.6 g protein daily) for first 3 months
Trial: 3225427
Drug: Intravenous cefamandole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefamandole and oral cephalexin
Trial: 23212610
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous and oral)
Trial: 28383710
Drug: ASP8477 (20/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8477 (20/30 mg BID)
Trial: 25257259
Drug: L-Tyrosine (TYR)
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-Tyrosine (TYR) supplement
Trial: 19162114
Drug: RIX4414 co-administered
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIX4414 co-administered with OPV
Trial: 19162114
Drug: Placebo co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo co-administered with OPV
Trial: 10446946
Drug: Hyperglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (blood glucose 9 to 11 mmol/L)
Trial: 10446946
Drug: Losartan administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan administration during hyperglycemia
Trial: 10446946
Drug: AngII infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AngII infusion (1.5 ng/kg per min) during hyperglycemia
Trial: 17699388
Drug: AngII infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AngII infusion
Trial: 10446946
Drug: Euglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (blood glucose 4 to 6 mmol/L)
Trial: 11739302
Drug: Triglycerides >200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglycerides >200 mg/dL
Trial: 9166835
Drug: VNCOP-B plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VNCOP-B plus G-CSF
Trial: 1586330
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (3mg) gel
Trial: 28159826
Drug: Aggressive titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive titration of vasoactive HF therapies
Trial: 17699177
Drug: Cardiac resynchronisation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronisation therapy
Trial: 11378012
Drug: Intravenous non-selective
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous non-selective endothelin antagonist
Trial: 11378012
Drug: Etanercept (TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (TNF receptor analogue)
Trial: 9131947
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose inhalation of fluticasone propionate (1000 micrograms)
Trial: 9131947
Drug: Repeated inhalations
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated inhalations of fluticasone propionate (1000 micrograms twice daily for 7 days)
Trial: 9131947
Drug: Intravenous dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose of fluticasone propionate (20 micrograms) as a reference
Trial: 3298405
Drug: Acyclovir (ACV)
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir (ACV) at 45 mg/kg/day by continuous infusion for 28 days
Trial: 3298405
Drug: Acyclovir (ACV)
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir (ACV) at 45 mg/kg/day by intermittent 8-hourly infusion for 28 days
Trial: 3298405
Drug: Acyclovir (ACV)
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir (ACV) treatment
Trial: 2583756
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (120 mg elemental iron as ferrous sulphate daily)
Trial: 2583756
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (240 mg elemental iron as ferrous sulphate daily)
Trial: 2583756
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (60 mg elemental iron as ferrous sulphate daily)
Trial: 25500684
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium valproate (20 mg/kg)
Trial: 25500684
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol (5 mg/1 ml)
Trial: 24001246
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) with monetary vouchers for stimulant-negative urine samples
Trial: 9197957
Drug: Detergent solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detergent solutions at 37 degrees C
Trial: 9197957
Drug: Detergent solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detergent solutions at 40 degrees C
Trial: 17982746
Drug: Intravenous pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pethidine
Trial: 4029895
Drug: Domperidone (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (equivalent dose to metoclopramide)
Trial: 4029895
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg) with spironolactone (300 mg/day)
Trial: 4029895
Drug: Domperidone (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (equivalent dose to metoclopramide) with spironolactone (300 mg/day)
Trial: 20716243
Drug: Antibiotics prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics prescribed
Trial: 20716243
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics prescribed
Trial: 29676944
Drug: CTS5 (Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTS5 (Clinical Treatment Score post-5 years)
Trial: 27749954
Drug: Caffeine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (100 mg) plus 5 doses of 100 mL decaffeinated coffee (total 500 mg caffeine)
Trial: 27749954
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose capsules) plus 5 doses of 100 mL decaffeinated coffee
Trial: 23131971
Drug: Health and
RxNorm normalized name: Culturelle Health and Wellness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health and wellness therapy group (n = 37)
Trial: 19944581
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol xinafoate (FSC) 100/50 microg twice daily
Trial: 19944581
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 100 microg twice daily
Trial: 11448906
Drug: Suramin treatment
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin treatment in patients with HRPC
Trial: 9649013
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg/day plus Ursodeoxycholic acid 600 mg/day (group 1)
Trial: 9649013
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 600 mg/day (group 2)
Trial: 8596756
Drug: Uraemic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uraemic group (HD treatment)
Trial: 2574054
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg acrivastine
Trial: 2570000
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg terfenadine at 1 h before challenge
Trial: 2570000
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg terfenadine at 2 h before challenge
Trial: 2570000
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg acrivastine at 1 and 2 h before challenge
Trial: 1192697
Drug: Dipeptide glycyl‐L‐alanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipeptide glycyl‐L‐alanine and its constituent amino acids
Trial: 1192697
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride solution (150 mmol/l)
Trial: 27465676
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy added to standard treatment (repositioning and an orthotic helmet)
Trial: 27465676
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (repositioning and an orthotic helmet)
Trial: 27465676
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy added to standard treatment
Trial: 22055763
Drug: Dose-dense weekly
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose-dense weekly paclitaxel (ddT) plus carboplatin
Trial: 22055763
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy including treatment administration (ddT)
Trial: 22055763
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy including treatment administration (q3T)
Trial: 19578177
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) patients
Trial: 14693625
Drug: Intrathecal meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal meperidine (0.2 mg/kg)
Trial: 31081593
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors or SGLT-1/2 inhibitors as adjunct to insulin
Trial: 31081593
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors or SGLT-1/2 inhibitors
Trial: 21091369
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac plus iliac crest normal saline infusion
Trial: 21091369
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac plus iliac crest bupivacaine infusion
Trial: 21091369
Drug: Iliac crest
RxNorm normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iliac crest bupivacaine infusion alone
Trial: 11597291
Drug: Ramipril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (up to 10 mg/d, n = 2837)
Trial: 11479247
Drug: Ramipril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (up to 10 mg/d)
Trial: 1790748
Drug: Timolol 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.1% eye drops, applied twice daily for one week before surgery
Trial: 1790748
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% eye drops, applied twice daily for one week before surgery
Trial: 1790748
Drug: Placebo eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops, applied twice daily for one week before surgery
Trial: 6803819
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (800 mg/day in the first week, 1 g/day in the second week)
Trial: 25892407
Drug: Sedation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation with daily wake up
Trial: 20973685
Drug: Bivalirudin 2
RxNorm normalized name: bivalirudin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin 2 mg/hour
Trial: 20973685
Drug: Heparin 400
RxNorm normalized name: heparin 40000 units/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 400 units/hour
Trial: 18621591
Drug: 100mg trazodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg trazodone tablet formulation
Trial: 10347132
Drug: No antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiviral therapy (Control)
Trial: 8817829
Drug: Recombinant hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hepatitis B vaccine (Engerix‐B, 10 micrograms dose‐1)
Trial: 8817829
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b (Hib) conjugate vaccine
Trial: 28843031
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (OGTT) prescribed to individuals scoring over 13 points on FINDRISC; 2.8% of population survey and 75.4% of opportunistic survey participants took the OGTT.
Trial: 28843031
Drug: Evaluation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of insulin resistance in individuals with prediabetes.
Trial: 17584825
Drug: Sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen (specifics not provided)
Trial: 17584825
Drug: Combination regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimen (specifics not provided)
Trial: 16132888
Drug: Ventilation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilation with lower tidal volume (V(T) of 6 ml/kg ideal body weight)
Trial: 16132888
Drug: Ventilation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilation with higher tidal volume (V(T) of 12 ml/kg ideal body weight)
Trial: 12034024
Drug: IFN-alpha2a (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha2a (3 x 10(6) IU) three times weekly for 8-16 weeks
Trial: 12034024
Drug: IFN-alpha2a (1.5-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha2a (1.5-6 x 10(6) IU) three times weekly for 12 months
Trial: 12034024
Drug: IFN-alpha2a re-administration
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha2a re-administration after discontinuation
Trial: 12034024
Drug: IFN-alpha2a treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha2a treatment
Trial: 2147175
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg/day) for 36 weeks followed by a placebo period of 4 weeks
Trial: 2147175
Drug: Encapsulated fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated fish oil (9 g/day) for 36 weeks with a subsequent period of 4 weeks in which fish oil placebo was given
Trial: 2147175
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg/day) for 12 weeks, propranolol plus fish oil capsules (9 g/day) for 12 weeks, propranolol plus fish oil placebo for 12 weeks
Trial: 6972101
Drug: Antrafenine 450
RxNorm normalized name: Antrafenine
DrugBank: Antrafenine (DB01419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antrafenine 450 mg/day
Trial: 6972101
Drug: Antrafenine 900
RxNorm normalized name: Antrafenine
DrugBank: Antrafenine (DB01419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antrafenine 900 mg/day
Trial: 6972101
Drug: Aspirin 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1.8 g/day
Trial: 31046719
Drug: Endurance plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurance plus balance training (twice weekly over 12 weeks)
Trial: 31046719
Drug: Endurance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurance training (twice weekly over 12 weeks)
Trial: 23644816
Drug: Telephone based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone based cognitive behavioral therapy (T-CBT)
Trial: 23644816
Drug: Face-to-face therapy
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face therapy (f2f)
Trial: 22852117
Drug: Curcumin 1000
RxNorm normalized name: Radiance Platinum Turmeric Curcumin 1000mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 1000 mg twice daily
Trial: 15526058
Drug: rabies vaccine
RxNorm normalized name: RABIES VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabies vaccine (control)
Trial: 11251139
Drug: Lidocaine (2%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (2%, 0.5 mL) mixed with radiopaque fluid (0.25 mL) injected after verifying target location using sensory and motor electrostimulation.
Trial: 9684395
Drug: Full intervention
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full intervention (referral to treatment)
Trial: 25703058
Drug: Gel cuff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel cuff applied to the most severely affected lower leg skin for 30 min daily
Trial: 18772244
Drug: Testosterone supplements
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone supplements
Trial: 16438129
Drug: Artekin (dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artekin (dihydroartemisinin 40 mg and piperaquine 320 mg) given once a day for 3 days (Group B)
Trial: 16438129
Drug: Artesunate 4
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate 4 mg/kg/day and mefloquine 8 mg/kg/day orally once a day for 3 days (Group A)
Trial: 16438129
Drug: Artekin (dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artekin (dihydroartemisinin 40 mg and piperaquine 320 mg)
Trial: 16438129
Drug: Artesunate 4
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate 4 mg/kg/day and mefloquine 8 mg/kg/day
Trial: 12903625
Drug: Pentaglobin (infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaglobin (infused intravenously at 12 mL/h for 3 days)
Trial: 12903625
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment period without Pentaglobin
Trial: 7564347
Drug: UP 269-6
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP 269-6 (180 mg)
Trial: 7564347
Drug: UP 269-6
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP 269-6 (>= 40 mg)
Trial: 1939923
Drug: Exposure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure treatment
Trial: 31770456
Drug: Itraconazole (P-glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (P-glycoprotein inhibitor)